Ligand Commits $33.75M to Pelthos PIPE, Holds 49.9% Voting Blocker Ahead of Castle Creek Merger
PTHS sits 20% above its 52-week low of $9.02.
Summary
Ligand disclosed a binding $33.75 million commitment to Pelthos's pre-merger PIPE — $3.675 million in Castle Creek bridge note plus $30.075 million cash — for Series B preferred converting at $19.67 and warrants struck at $0.0001, alongside a 49.9% voting cap.
Key Events · Ownership and Investor Activity · PTHS
-
Ligand Anchors $33.75M PIPE
Ligand agreed to buy 33,750 Series B preferred shares (stated value $1,000) plus warrants on 291,688 common shares for $33,750,000, with $3,675,000 paid via transfer of the Castle Creek bridge note and $30,075,000 expected in cash.
-
Conversion and Warrant Terms
Series B converts at $19.67 per share (voting conversion price $16.54); warrants carry a $0.0001 strike, become exercisable 180 days after closing and run 10 years, with a 49.99% ownership blocker.
-
Ligand Already Holds 38.2%
Ligand beneficially owns 1,500,000 common shares (~38.2%), 34,278.681 Series A preferred convertible into 3,427,868.1 shares (~66.6% of Series A), and a $9.0M convertible note for 261,309 shares, capped at 49.9% of voting power.
-
PIPE Needs $57.5M to Close
The Concurrent Financing requires at least $57.5 million from investors and closes immediately before the merger; the merger has a February 1, 2027 outside date, extendable to March 31, 2027.
Analysis · PTHS · Life Sciences
Ligand, already Pelthos's largest holder at roughly 38.2% of the common stock, is anchoring the PIPE that must close before the Castle Creek merger can complete. It is buying 33,750 Series B preferred shares at $1,000 stated value plus warrants on 291,688 common shares for $33.75 million, of which $3.675 million is paid by handing Pelthos a Castle Creek bridge note it already owns and $30.075 million in cash. The Series B converts at $19.67 — well above today's $10.78 — so the effective share count from this tranche is smaller than the headline dollars suggest, but the 49.99% ownership cap and the $0.0001 warrant strike leave Ligand with a dominant, cheaply expandable stake. The deal still needs at least $57.5 million in total PIPE commitments, an effective S-4, HSR clearance and NYSE American listing approval, with a February 1, 2027 outside date (extendable to March 31, 2027).
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTHS was trading at $10.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.3M. The 52-week trading range was $9.02 to $37.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.